{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:49:38Z","timestamp":1791089378811,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,3,5]],"date-time":"2010-03-05T00:00:00Z","timestamp":1267747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2010,3,5]],"date-time":"2010-03-05T00:00:00Z","timestamp":1267747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Disturbance of the pro-coagulatant and anti-coagulant balance is associated with a poor outcome from critical illness. The objective of this study is to determine whether the Factor V Leiden (FVL) mutation is associated with susceptibility to or death from critical illness.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>A genetic association study involving four case cohorts comprising two Gram negative sepsis, one invasive pneumococcal disease and one intensive care unit cohort with a total of 1,249 patients. Controls were derived from a population-based cohort study (N = 8,147). DNA from patients and controls was genotyped for the FVL mutation.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>When all patients were investigated together no significant difference in the frequency of FVL mutation was observed compared with controls (odds ratio (OR), 1.03; 95% confidence interval (CI), 0.83 to 1.29). However, when stratified among patients admitted to intensive care (N = 237), susceptibility and the likelihood of long-term death was influenced by the FVL mutation. In adjusted logistic regression analysis, FVL carriers had an increased risk of ICU admission compared to non-carriers (OR 1.62; 95% CI, 1.08 to 2.42). In adjusted Cox regression analysis, FVL carriers were at increased risk of long-term death compared to non-carriers (relative risk 1.78; 95% CI, 1.13 to 2.81). FVL carrier status did not predict either susceptibility to or outcome from Gram negative, <jats:italic>Escherichia coli<\/jats:italic> or <jats:italic>Streptococcus pneumoniae<\/jats:italic> sepsis.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Overall, the FVL mutation did not appear to increase the risk of admission due to severe invasive infections. Nevertheless, in the subgroup of patients admitted to intensive care an increased risk and a poorer long-term outcome for individuals with critical illness were observed for FVL mutation carriers.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/cc8899","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T18:14:13Z","timestamp":1269972853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Influence of Factor V Leiden on susceptibility to and outcome from critical illness: a genetic association study"],"prefix":"10.1186","volume":"14","author":[{"given":"Thomas","family":"Benfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ejrn\u00e6s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Juul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Helweg-Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Munthe-Fog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte","family":"Kronborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne Ring","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tybj\u00e6rg-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Garred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,5]]},"reference":[{"key":"8329_CR1","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0140-6736(96)07493-4","volume":"349","author":"CJ Murray","year":"1997","unstructured":"Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997, 349: 1269-1276. 10.1016\/S0140-6736(96)07493-4.","journal-title":"Lancet"},{"key":"8329_CR2","volume-title":"The World Health Report: 2003: Shaping the Future","author":"R Beaglehole","year":"2003","unstructured":"Beaglehole R, Irwin A, Prentice T: The World Health Report: 2003: Shaping the Future. 2003, World Health Organization"},{"key":"8329_CR3","volume-title":"Deaths: final data for 2002. National Vital Statistics Report","author":"KD Kochanek","year":"2004","unstructured":"Kochanek KD, Murphy SL, Anderson RN, Scott C: Deaths: final data for 2002. National Vital Statistics Report. 2004, Hyattsville, Md., National Center for Health Statistics, 53 (8):"},{"key":"8329_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1473-3099(07)70185-8","volume":"7","author":"PY Bochud","year":"2007","unstructured":"Bochud PY, Bochud M, Telenti A, Calandra T: Innate immunogenetics: a tool for exploring new frontiers of host defence. Lancet Infect Dis. 2007, 7: 531-542. 10.1016\/S1473-3099(07)70185-8.","journal-title":"Lancet Infect Dis"},{"key":"8329_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/369064a0","volume":"369","author":"RM Bertina","year":"1994","unstructured":"Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, Velden van der PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994, 369: 64-67. 10.1038\/369064a0.","journal-title":"Nature"},{"key":"8329_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.7326\/0003-4819-140-5-200403020-00008","volume":"140","author":"K Juul","year":"2004","unstructured":"Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG: Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med. 2004, 140: 330-337.","journal-title":"Ann Intern Med"},{"key":"8329_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2002-01-0290","volume":"101","author":"KG Mann","year":"2003","unstructured":"Mann KG, Kalafatis M: Factor V: a combination of Dr Jekyll and Mr Hyde. Blood. 2003, 101: 20-30. 10.1182\/blood-2002-01-0290.","journal-title":"Blood"},{"key":"8329_CR8","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2003-06-1789","volume":"102","author":"BA Kerlin","year":"2003","unstructured":"Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut J-F: Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003, 102: 3085-3092. 10.1182\/blood-2003-06-1789.","journal-title":"Blood"},{"key":"8329_CR9","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1097\/CCM.0b013e318174373d","volume":"36","author":"M Adamzik","year":"2008","unstructured":"Adamzik M, Frey UH, Riemann K, Sixt S, Lehmann N, Siffert W, Peters J: Factor V Leiden mutation is associated with improved 30-day survival in patients with acute respiratory distress syndrome. Crit Care Med. 2008, 36: 1776-1779. 10.1097\/CCM.0b013e318174373d.","journal-title":"Crit Care Med"},{"key":"8329_CR10","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.1097\/01.CCM.0000126122.34119.D1","volume":"32","author":"SB Yan","year":"2004","unstructured":"Yan SB, Nelson DR: Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med. 2004, 32: S239-S246. 10.1097\/01.CCM.0000126122.34119.D1.","journal-title":"Crit Care Med"},{"key":"8329_CR11","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1097\/01.CCM.0000228918.30931.E8","volume":"34","author":"LW Bruggemann","year":"2006","unstructured":"Bruggemann LW, Schoenmakers SH, Groot AP, Reitsma PH, Spek CA: Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med. 2006, 34: 2201-2206. 10.1097\/01.CCM.0000228918.30931.E8.","journal-title":"Crit Care Med"},{"key":"8329_CR12","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1182\/blood-2008-07-170506","volume":"113","author":"H Sun","year":"2009","unstructured":"Sun H, Wang X, Degen JL, Ginsburg D: Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood. 2009, 113: 1358-1364. 10.1182\/blood-2008-07-170506.","journal-title":"Blood"},{"key":"8329_CR13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/00006454-199910000-00011","volume":"18","author":"S Kondaveeti","year":"1999","unstructured":"Kondaveeti S, Hibberd ML, Booy R, Nadel S, Levin M: Effect of the Factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J. 1999, 18: 893-896. 10.1097\/00006454-199910000-00011.","journal-title":"Pediatr Infect Dis J"},{"key":"8329_CR14","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1086\/497167","volume":"192","author":"TL Benfield","year":"2005","unstructured":"Benfield TL, Dahl M, Nordestgaard BG, Tybjaerg-Hansen A: Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome: a population-based study. J Infect Dis. 2005, 192: 1851-1857. 10.1086\/497167.","journal-title":"J Infect Dis"},{"key":"8329_CR15","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJM199805283382203","volume":"338","author":"A Tybjaerg-Hansen","year":"1998","unstructured":"Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG: Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med. 1998, 338: 1577-1584. 10.1056\/NEJM199805283382203.","journal-title":"N Engl J Med"},{"key":"8329_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1471-2334-7-108","volume":"7","author":"KM Jessen","year":"2007","unstructured":"Jessen KM, Lindboe SB, Petersen AL, Eugen-Olsen J, Benfield T: Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis. BMC Infect Dis. 2007, 7: 108-10.1186\/1471-2334-7-108.","journal-title":"BMC Infect Dis"},{"key":"8329_CR17","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","volume":"101","author":"RC Bone","year":"1992","unstructured":"Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine. Chest. 1992, 101: 1644-1655. 10.1378\/chest.101.6.1644.","journal-title":"Chest"},{"key":"8329_CR18","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1086\/379044","volume":"188","author":"P Garred","year":"2003","unstructured":"Garred P, Strom J, Quist L, Taaning E, Madsen HO: Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis. 2003, 188: 1394-1403. 10.1086\/379044.","journal-title":"J Infect Dis"},{"key":"8329_CR19","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1016\/j.vaccine.2008.04.040","volume":"26","author":"ZB Harboe","year":"2008","unstructured":"Harboe ZB, Valentiner-Branth P, Benfield TL, Christensen JJ, Hjuler T, Kaltoft M, Krogfelt KA, Lambertsen L, Konradsen HB: Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005. Vaccine. 2008, 26: 3765-3771. 10.1016\/j.vaccine.2008.04.040.","journal-title":"Vaccine"},{"key":"8329_CR20","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1086\/340216","volume":"185","author":"G Kronborg","year":"2002","unstructured":"Kronborg G, Weis N, Madsen HO, Pedersen SS, Wejse C, Nielsen H, Skinhoj P, Garred P: Variant mannose-binding lectin alleles are not associated with susceptibility to or outcome of invasive pneumococcal infection in randomly included patients. J Infect Dis. 2002, 185: 1517-1520. 10.1086\/340216.","journal-title":"J Infect Dis"},{"key":"8329_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2002-01-0111","volume":"100","author":"K Juul","year":"2002","unstructured":"Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG: Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood. 2002, 100: 3-10. 10.1182\/blood-2002-01-0111.","journal-title":"Blood"},{"key":"8329_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJM199702063360602","volume":"336","author":"P Simioni","year":"1997","unstructured":"Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A: The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997, 336: 399-403. 10.1056\/NEJM199702063360602.","journal-title":"N Engl J Med"},{"key":"8329_CR23","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/clinchem\/46.8.1191","volume":"46","author":"FA van den Bergh","year":"2000","unstructured":"Bergh van den FA, van Oeveren-Dybicz AM, Bon MA: Rapid single-tube genotyping of the factor V Leiden and prothrombin mutations by real-time PCR using dual-color detection. Clin Chem. 2000, 46: 1191-1195.","journal-title":"Clin Chem"},{"key":"8329_CR24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJM200103083441001","volume":"344","author":"GR Bernard","year":"2001","unstructured":"Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainault J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely W, Fisher CJ: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001, 344: 699-709. 10.1056\/NEJM200103083441001.","journal-title":"N Engl J Med"},{"key":"8329_CR25","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1056\/NEJMoa041747","volume":"351","author":"L Smeeth","year":"2004","unstructured":"Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P: Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004, 351: 2611-2618. 10.1056\/NEJMoa041747.","journal-title":"N Engl J Med"},{"key":"8329_CR26","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(06)68474-2","volume":"367","author":"L Smeeth","year":"2006","unstructured":"Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P: Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006, 367: 1075-1079. 10.1016\/S0140-6736(06)68474-2.","journal-title":"Lancet"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc8899.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/cc8899\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc8899.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:18:22Z","timestamp":1728303502000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/cc8899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,5]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2010,4]]}},"alternative-id":["8329"],"URL":"https:\/\/doi.org\/10.1186\/cc8899","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,5]]},"assertion":[{"value":"20 November 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R28"}}